Venetoclax in the Therapeutic Strategy for BPDCN Management.

Date publication

août 2025

Journal

EJHaem

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Dr BOIDOT Romain , Pr GARNACHE-OTTOU Francine , Dr KROEMER Marie , Dr ANGELOT-DELETTRE Fanny , Dr RENOSI Florian

Tous les auteurs :
Poussard M, Fredon M, Belakri I, Biichle S, Renosi F, Seffar E, Boichut M, Boidot R, Bôle-Richard E, Bonnefoy F, Kroemer M, Bonnot-Perrin S, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40842922

Résumé

Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials. However, several case reports have reported relapses after prolonged treatment, and development of resistance. To date, no study has investigated resistance to venetoclax in BPDCN. Therefore, we sought to investigate the mechanisms that trigger resistance during treatment.

Référence

EJHaem. 2025 08;6(4):e70070